Patents Represented by Attorney, Agent or Law Firm Steve T. Zelson
  • Patent number: 5882718
    Abstract: A method for treating an aqueous protein solution so as to kill microorganisms which may be present therein, but without causing coagulation, comprises either (1) mixing the solution with sufficient enzymatically produced protein hydrolysate (H1) to prevent coagulation of the mixture when the mixture is subsequently subjected to a heat treatment to kill microorganisms, and then subjecting the mixture to such a heat treatment, or (2) using one or more enzymes to hydrolyze protein in the aqueous protein solution to an extent sufficient to prevent coagulation of the resulting liquid hydrolysate (H2) when it is subsequently subjected to a heat treatment to kill microorganisms, and then subjecting the liquid hydrolysate (H2) to such a heat treatment. The use of aqueous protein solutions treated in this manner in the production of a foodstuff, such as a meat-based foodstuff, contributes very significantly to reducing any risk of contamination of the foodstuff by harmful microorganisms.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Klaus Pommer, Egon Christensen
  • Patent number: 5882883
    Abstract: The invention relates to an improved process for the production of a secondary metabolite comprising (i) fermentation of a microorganism capable of producing said secondary metabolite, and (ii) recovering said metabolite in substantially pure form. Said microorganism has been modified in a manner whereby the expression of one or more of the DNA sequences coding for (a) peptide(s), (a) protein(s) or (an) enzyme(s), involved in or interfering with the biosynthetic pathway of said secondary metabolite, is regulated differently from the regulation of said DNA sequence(s) in the original microorganism. Further contemplated is a process for production of said microorganism, a DNA construct, a vector or transformation vehicle, a microorganism capable of producing secondary metabolite and finally a secondary metabolite product.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Michi Egel-Mitani, Henrik M.o slashed.llgaard, Svend Kaasgaard, Klaus Nyegaard Kristiansen
  • Patent number: 5882911
    Abstract: The present invention relates to DNA sequences encoding a rhamnogalacturonase which comprises(a) the DNA sequence of nucleotides 64-1587 of SEQ ID NO:1;(b) a DNA sequence which hybridizes to the same probe as nucleotides 64-1587 of SEQ ID NO:1 under conditions of presoaking in 5.times.SSC and prehybridizing for 1 hour at -40.degree. C. in a solution of 5.times.SSC, 5.times.Denhardt's solution, 50 mM sodium phosphate, pH 6.8, and 50 mg of denatured sonicated calf thymus DNA, followed by hybridization in the same solution supplemented with 50 .mu.Ci 32-P-dCTP labelled probe for 18 h at -40.degree. C., followed by washing three times in 2.times.SSC, 0.2% SDS at 40.degree. C. for 30 minutes; or(c) a DNA sequence encoding an amino acid sequence having amino acids 20-527 of the sequence of SEQ ID NO;2.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Lene Venke Kofod, Lene Nonboe Andersen, Henrik Dalb.o slashed.ge, Markus Sakari Kauppinen, Stephan Christgau, Hans Peter Heldt-Hansen, Claus Christophersen, Per Munk Nielsen, Alphons Gerard Joseph Voragen, Hendrik Arie Schols
  • Patent number: 5882906
    Abstract: The present invention relates to an amylase isolated from Staphalothermus marinus, DSM 3639, having a temperature optima of 95.degree.-105.degree. C., determined at pH 5.5 and a pH optima of 4.5 to 5.5, determined at 95.degree. C. The amylase can be employed in the production of sweeteners and ethanol.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Carsten Sj.o slashed.holm, Garabed Antranikian
  • Patent number: 5883118
    Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: March 16, 1999
    Assignee: Nova Nordisk A/S
    Inventors: Michael Shalmi, Niels Dyhr Christensen, Niels Korsgaard, Birgitte Hjort Guldhammer
  • Patent number: 5882888
    Abstract: Multicopy strains of gram-positive bacteria carrying multiple copies of a DNA sequence of interest may be constructed by use of a method involving introduction of a DNA construct comprising the DNA sequence of interest into the genome of the recipient cell by transposition and subsequent deletion of a marker gene used for selection of the cells having received the DNA construct by a resolution system. The multicopy strains are preferably free from a gene encoding an undesirable marker such as an antibiotic resistance marker.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventor: Steen Troels J.o slashed.rgensen
  • Patent number: 5879921
    Abstract: The invention is directed to alkaline glucose oxidases comprising novel peptide sequences. Furthermore, the invention relates to methods for producing and using said glucose oxidases.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: March 9, 1999
    Assignees: Novo Nordisk A/S, Novo Nordisk Biotech, Inc.
    Inventors: Joel R. Cherry, Randy M. Berka, Torben Halkier
  • Patent number: 5879664
    Abstract: A fungal protein disulfide isomerase obtainable from fungal species belonging to Aspergillus, especially A. oryzae, or A. niger, is disclosed. Furthermore sequences for recombinant production of the protein disulfide isomerase are disclosed.
    Type: Grant
    Filed: December 11, 1995
    Date of Patent: March 9, 1999
    Assignee: Novo Nordisk A/S
    Inventor: Carsten Mailand Hjort
  • Patent number: 5879509
    Abstract: In the production of pulp and paper from starch-coated paper, the deinking effect can be improved by including a treatment with a starch-degrading enzyme e.g. amylase or a debranching enzyme. The process comprises enzyme treatment before, during or after disintegration of the paper to produce pulp, followed by separation of ink particles.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: March 9, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Masaki Sharyo, Hidesato Shimoto, Hiromichi Sakaguchi
  • Patent number: 5874428
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: March 28, 1996
    Date of Patent: February 23, 1999
    Assignee: Novo Nordisk Als
    Inventors: Florenzio Zaragossa D.o slashed.rwald, Knud Erik Andersen, Rolf Hohlweg, Peter Madsen, Tine Krogh J.o slashed.rgensen, Uffe Bang Olsen, Henrik Sune Andersen, Svend Treppendahl, Polivka Zdenek, Silhankova Alexandra, Sindelar Karel
  • Patent number: 5874274
    Abstract: The present invention relates to a process for reducing the viscosity of a plant material, which process comprises treating the plant material with a xylanase having i) a WSPS per mg protein added which is higher than 0,06, and/or ii) a WSPU per mg protein added which is higher than 15, and/or iii) a specific activity of more than 0,053 FVRU/mg protein. Further, the invention relates to use of a xylanase preparation for separating a plant material, such as wheat, into separate useful components as well as processes for such viscosity reduction or separation.
    Type: Grant
    Filed: September 23, 1996
    Date of Patent: February 23, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Tina Sejersg.ang.ard Jakobsen, Hans Peter Heldt-Hansen, Lene Venke Kofod, Christian Lorentz Bagger, Anette Mullertz
  • Patent number: 5874558
    Abstract: A process for expression of a protein product in Aspergillus oryzae is disclosed. The process comprises transforming Aspergillus oryzae with a vector system comprising DNA-sequences encoding functions facilitating gene expression, a suitable marker for selection of transformants, and a DNA-sequence encoding the desired protein product. The process enables industrial production of many different polypeptides and proteins in A. oryzae. Examples of such products are chymosin or prochymosin and other rennets, proteases, lipases and amylases. Also disclosed is an effective promoter for expression of a protein in Aspergillus. A preferred promoter is the TAKA-amylase promoter or functional parts thereof. There is also provided a process for the production of a recombinant Humicola lipase. The recombinant Humicola lipase from A. oryzae differs from the native lipase in having a greater glycosylation and in exhibiting an improved thermostability.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: February 23, 1999
    Assignee: Novo Nordisk
    Inventors: Esper Boel, Tove Christensen, Helle Fabricius Woldike
  • Patent number: 5874275
    Abstract: The present invention relates to polypeptides having mutanase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to oral cavity compositions and methods for degrading mutan.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: February 23, 1999
    Assignees: Novo Nordisk A/S, Novo Nordisk Biotech, Inc.
    Inventors: Randy M Berka, Stephan Christgau, Torben Halkier, Jeff Shuster, Claus Crone Fuglsang
  • Patent number: 5871991
    Abstract: The present invention relates to Aspergillus oryzae 5-aminolevulinic acid synthases and isolated nucleic acid fragments comprising nucleic acid sequences encoding the 5-aminolevulinic acid synthases as well as nucleic acid constructs, vectors, and recombinant host cells comprising the nucleic acid sequences. The invention also relates to methods of producing the 5-aminolevulinic acid synthases.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: February 16, 1999
    Assignee: Novo Nordisk BioTech, Inc.
    Inventors: Susan L. Elrod, Joel R. Cherry
  • Patent number: 5871966
    Abstract: A partial amino acid sequence of an endo-.beta.-1,4-glucanase obtainable by means of Aspergillus aculeatus is described, and also corresponding recombinant DNA sequences, vectors and transformed hosts. Use of the endo-.beta.- 1,4-glucanase or a pectinase preparation enriched with the endo-.beta.-1,4-glucanase for degradation or modification of plant cell walls is described.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: February 16, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Lene Venke Kofod, Lene Nonboe Andersen, Markus Sakari Kauppinen, Stephan Christgau, Henrik Dalb.o slashed.ge, Hans Sejr Olsen, Jens Breinholt
  • Patent number: 5869602
    Abstract: The present invention relates to a pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: February 9, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Ib Jonassen, Svend Havelund, Per Hertz Hansen, Peter Kurtzhals, John Halstr.o slashed.m
  • Patent number: 5866590
    Abstract: The present invention provides a new stable pharmaceutical composition containing tiagabine hydrochloride as active ingredient.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: February 2, 1999
    Assignee: Novo Nordisk A/S
    Inventors: J.o slashed.rgen Ryhl Svensson, Lars Nygaard, Tina Meinertz Andersen, Helle Weibel, Thyge Borup Hjorth
  • Patent number: 5866526
    Abstract: An enzyme preparation comprising a modified enzyme selected from the group consisting of an amylase, lipase, oxidorcductase, pectinace or hemicellulase, the modified enzyme having an improved performance due to an alkaline pI and/or increased surface activity obtained by chemical modification or amino acid substitution, is useful e.g., in detergents, in baking flour, in animal feed, in the manufacture of cellulosic fabrics and for the treatment of lignocellulosic fibers.
    Type: Grant
    Filed: May 2, 1996
    Date of Patent: February 2, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Arne Agerlin Olsen, Allan Svendsen, Kim Borch, Henrik Lund, Marianne Thellersen, Peter Rosholm, Niels Munk
  • Patent number: 5866118
    Abstract: The present invention relates to isolated polypeptides having phytase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to composite feeds and methods of reducing phytate levels.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: February 2, 1999
    Assignee: Novo Nordisk Biotech, Inc.
    Inventors: Randy M. Berka, Michael W. Rey, Alan V. Klotz
  • Patent number: 5866392
    Abstract: Enzyme exhibiting cellobiose oxidase activity, which enzyme has a relative activity of at least 70% at a pH of about 9 and a temperature of about 50.degree. C. An enzymatic agent comprising cellobiose oxidase and an endoglycanase and/or oxidoreductase. A process of bleaching paper pulp using cellobiose oxidase.
    Type: Grant
    Filed: June 24, 1996
    Date of Patent: February 2, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Charlotte Schou, Martin Schulein, Thomas Vollmond